» Articles » PMID: 32203286

T Cell Subsets and Functions in Atherosclerosis

Overview
Journal Nat Rev Cardiol
Date 2020 Mar 24
PMID 32203286
Citations 316
Authors
Affiliations
Soon will be listed here.
Abstract

Atherosclerosis is a chronic inflammatory disease of the arterial wall and the primary underlying cause of cardiovascular disease. Data from in vivo imaging, cell-lineage tracing and knockout studies in mice, as well as clinical interventional studies and advanced mRNA sequencing techniques, have drawn attention to the role of T cells as critical drivers and modifiers of the pathogenesis of atherosclerosis. CD4 T cells are commonly found in atherosclerotic plaques. A large body of evidence indicates that T helper 1 (T1) cells have pro-atherogenic roles and regulatory T (T) cells have anti-atherogenic roles. However, T cells can become pro-atherogenic. The roles in atherosclerosis of other T cell subsets such as T2, T9, T17, T22, follicular helper T cells and CD28 T cells, as well as other T cell subsets including CD8 T cells and γδ T cells, are less well understood. Moreover, some T cells seem to have both pro-atherogenic and anti-atherogenic functions. In this Review, we summarize the knowledge on T cell subsets, their functions in atherosclerosis and the process of T cell homing to atherosclerotic plaques. Much of our understanding of the roles of T cells in atherosclerosis is based on findings from experimental models. Translating these findings into human disease is challenging but much needed. T cells and their specific cytokines are attractive targets for developing new preventive and therapeutic approaches including potential T cell-related therapies for atherosclerosis.

Citing Articles

Dissecting Causal Relationship Among Immune Cells, Plasma Metabolites and Coronary Atherosclerosis: A Mendelian Randomization Study.

Cao Q, Liu J, Sun J, Qian S, Song J, Zheng H Immunotargets Ther. 2025; 14:175-188.

PMID: 40066076 PMC: 11892494. DOI: 10.2147/ITT.S508042.


A nanovaccine for immune activation and prophylactic protection of atherosclerosis in mouse models.

Zhang L, Al-Ammari A, Zhu D, Zhang H, Zhou P, Zhi X Nat Commun. 2025; 16(1):2111.

PMID: 40025093 PMC: 11873251. DOI: 10.1038/s41467-025-57467-5.


The Interplay Between Immunity, Inflammation and Endothelial Dysfunction.

Chee Y, Dalan R, Cheung C Int J Mol Sci. 2025; 26(4).

PMID: 40004172 PMC: 11855323. DOI: 10.3390/ijms26041708.


Incidence and clinical impact of coronary artery disease confirmed by coronary CT angiography in patients with interstitial lung disease.

Kwak H, Kim H, Koo H, Lee S, Lee P, Kim T BMC Pulm Med. 2025; 25(1):88.

PMID: 39987066 PMC: 11847390. DOI: 10.1186/s12890-025-03554-8.


Targeting gut microbiota to regulate the adaptive immune response in atherosclerosis.

Giakomidi D, Ishola A, Nus M Front Cardiovasc Med. 2025; 12:1502124.

PMID: 39957996 PMC: 11825770. DOI: 10.3389/fcvm.2025.1502124.


References
1.
Potteaux S, Combadiere C, Esposito B, Lecureuil C, Ait-Oufella H, Merval R . Role of bone marrow-derived CC-chemokine receptor 5 in the development of atherosclerosis of low-density lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol. 2006; 26(8):1858-63. DOI: 10.1161/01.ATV.0000231527.22762.71. View

2.
Mailer R, Gistera A, Polyzos K, Ketelhuth D, Hansson G . Hypercholesterolemia Induces Differentiation of Regulatory T Cells in the Liver. Circ Res. 2017; 120(11):1740-1753. DOI: 10.1161/CIRCRESAHA.116.310054. View

3.
van Wanrooij E, de Jager S, van Es T, De Vos P, Birch H, Owen D . CXCR3 antagonist NBI-74330 attenuates atherosclerotic plaque formation in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2007; 28(2):251-7. DOI: 10.1161/ATVBAHA.107.147827. View

4.
Koenen R, von Hundelshausen P, Nesmelova I, Zernecke A, Liehn E, Sarabi A . Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. Nat Med. 2009; 15(1):97-103. DOI: 10.1038/nm.1898. View

5.
Getz G, Reardon C . Natural killer T cells in atherosclerosis. Nat Rev Cardiol. 2017; 14(5):304-314. DOI: 10.1038/nrcardio.2017.2. View